Last reviewed · How we verify
Postencephalitic parkinsonism
Approved treatments
- Inbrija · Merz
Levodopa works by crossing the blood-brain barrier and being converted into dopamine, a neurotransmitter that helps regulate movement and coordination. - Sinemet Cr · Aton
Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinson's disease symptoms. - Parlodel · Esjay Pharma
- Artane
- Lodosyn · University of Miami
- Cogentin · University of Southern California
- Artane
- Kemadrine
- Akineton · AbbVie
- Gocovri · Endo
- Cogentin
- GOCOVRI · Oregon Health and Science University
- Amantadin · Centre Hospitalier Universitaire de Nice
- Bromocriptin · University Hospital, Bonn
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Postencephalitic parkinsonism patent landscape — cliff calendar, originator estates, attackable patents
- Postencephalitic parkinsonism treatment landscape brief
- Postencephalitic parkinsonism treatment updates RSS
Frequently asked questions about Postencephalitic parkinsonism
What drugs treat Postencephalitic parkinsonism?
Tracked treatments include Inbrija, Sinemet Cr, Parlodel, Artane, Lodosyn, Cogentin, Kemadrine, Akineton.
What is the treatment for Postencephalitic parkinsonism?
Standard treatment for Postencephalitic parkinsonism includes Inbrija, Sinemet Cr, Parlodel, Artane, Lodosyn. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Postencephalitic parkinsonism patent cliff · Postencephalitic parkinsonism CI report
- Treatment: Inbrija · Merz
- Treatment: Sinemet Cr · Aton
- Treatment: Parlodel · Esjay Pharma
- Treatment: Artane
- Treatment: Lodosyn · University of Miami
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing